# PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

> **NCT06066255** · PHASE2 · UNKNOWN · sponsor: **Institut Paoli-Calmettes** · enrollment: 27 (estimated)

## Conditions studied

- Hematological Malignancy

## Interventions

- **DRUG:** Thymoglobulin Injectable Product

## Key facts

- **NCT ID:** NCT06066255
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-31
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066255, "PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06066255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*